We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+6.55%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$467M
AUM Growth
-$27.9M
Cap. Flow
-$12.7M
Cap. Flow %
-2.72%
Top 10 Hldgs %
72.26%
Holding
31
New
2
Increased
2
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$21.5M
2
ZGNX
Zogenix, Inc.
ZGNX
+$4.03M
3
SLNO
Soleno Therapeutics
SLNO
+$2.1M
4
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$49.7K

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$29.5M
2
AIMT
Aimmune Therapeutics
AIMT
+$4.3M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$3.19M
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$2.13M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$957K

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Materials 2.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
26
CRISPR Therapeutics
CRSP
$4.68B
$2.31M 0.5%
98,511
-50,367
-34% -$957K
VIRX
27
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.84M 0.4%
14,286
– –
TMBR
28
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$1.52M 0.33%
920
-20
-2% -$54.5K
AKTX
29
Akari Therapeutics
AKTX
$14.8M
$1.5M 0.32%
432
– –
SLNOW
30
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$27K 0.01%
188,772
– –
RVNC
31
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-77,373
Closed -$2.13M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Vivo Capital held 31 positions worth $467M, down 5.6% from $495M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Vivo Capital's Q4 2017 filing shows 2 new, 2 increased, 6 reduced and 1 closed positions. Its largest new stake was Apellis Pharmaceuticals: 1,457,834 shares worth $31.6M. The largest sale was Aclaris Therapeutics, an estimated $29.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q4 2017 buy was Apellis Pharmaceuticals: 1,457,834 shares worth $31.6M.
  • Vivo Capital added most to Soleno Therapeutics in Q4 2017, an estimated $2.1M increase.
  • Vivo Capital's biggest Q4 2017 reduction was Aclaris Therapeutics, cutting an estimated $29.5M.
  • Vivo Capital fully exited Revance Therapeutics, Inc. in Q4 2017, selling an estimated $2.13M.
  • Vivo Capital's ten largest holdings make up 72% of its $467M portfolio in Q4 2017.
  • Vivo Capital opened 2 new positions and closed 1 in Q4 2017.
  • Vivo Capital's portfolio value fell 5.6% quarter-over-quarter to $467M.

Based on Vivo Capital's 13F filing for Q4 2017, filed 9 Feb 2018.